
    
      Patients with liver predominant cholangiocarcinoma or pancreatic cancer will be considered
      for the trial. The patients wre being treated in groups of thre patients. Each three patients
      receive a pre-specified dose of gemcitabine with full dose radioembolization using
      theraspheres. If no significant side effects are observed then three additional three
      patients will be treated with a higher dose of gemcitabine. The purpose to identify the
      highest dose of gemcitabine that can be safely combined with theraspheres.
    
  